JP4607319B2 - ビタミンｐｐ化合物の使用 - Google Patents

ビタミンｐｐ化合物の使用 Download PDF

Info

Publication number
JP4607319B2
JP4607319B2 JP2000544324A JP2000544324A JP4607319B2 JP 4607319 B2 JP4607319 B2 JP 4607319B2 JP 2000544324 A JP2000544324 A JP 2000544324A JP 2000544324 A JP2000544324 A JP 2000544324A JP 4607319 B2 JP4607319 B2 JP 4607319B2
Authority
JP
Japan
Prior art keywords
pyridin
butyl
compounds
acrylamide
nicotinamide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2000544324A
Other languages
English (en)
Japanese (ja)
Other versions
JP2002512190A (ja
JP2002512190A5 (enExample
Inventor
ビダーマン，エルフィ
ハスマン，マクス
ローゼル，ローランド
ラッテル，ベンノ
レイター，フレイドマン
シェイン，バーバラ
シェマインダ，イザベル
ザイベル，クラオス
フォーグ，クラオス
ヴォジコウスキー，カッツイェ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Astellas Deutschland GmbH
Original Assignee
Astellas Deutschland GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astellas Deutschland GmbH filed Critical Astellas Deutschland GmbH
Publication of JP2002512190A publication Critical patent/JP2002512190A/ja
Publication of JP2002512190A5 publication Critical patent/JP2002512190A5/ja
Application granted granted Critical
Publication of JP4607319B2 publication Critical patent/JP4607319B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4406—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 3, e.g. zimeldine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2000544324A 1998-04-22 1999-04-21 ビタミンｐｐ化合物の使用 Expired - Fee Related JP4607319B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE19818044A DE19818044A1 (de) 1998-04-22 1998-04-22 Verwendung von Vitamin-PP-Verbindungen
DE19818044.6 1998-04-22
PCT/EP1999/002686 WO1999053920A1 (en) 1998-04-22 1999-04-21 Use of vitamin pp compounds

Publications (3)

Publication Number Publication Date
JP2002512190A JP2002512190A (ja) 2002-04-23
JP2002512190A5 JP2002512190A5 (enExample) 2010-02-25
JP4607319B2 true JP4607319B2 (ja) 2011-01-05

Family

ID=7865483

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2000544324A Expired - Fee Related JP4607319B2 (ja) 1998-04-22 1999-04-21 ビタミンｐｐ化合物の使用

Country Status (9)

Country Link
US (1) US20100227896A1 (enExample)
EP (1) EP1079832B1 (enExample)
JP (1) JP4607319B2 (enExample)
AT (1) ATE311186T1 (enExample)
AU (1) AU3928299A (enExample)
DE (2) DE19818044A1 (enExample)
DK (1) DK1079832T3 (enExample)
ES (1) ES2253890T3 (enExample)
WO (1) WO1999053920A1 (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000007580A2 (en) * 1998-08-03 2000-02-17 N-Gene Kutató Kft. Pharmaceutical compositions against autoimmune diseases
GB0104240D0 (en) 2001-02-21 2001-04-11 Clariant Int Ltd Copolymer composition having pigment like properties
EP1348434A1 (en) * 2002-03-27 2003-10-01 Fujisawa Deutschland GmbH Use of pyridyl amides as inhibitors of angiogenesis
US8067457B2 (en) 2005-11-01 2011-11-29 Millennium Pharmaceuticals, Inc. Compounds useful as antagonists of CCR2
WO2007053499A2 (en) 2005-11-01 2007-05-10 Millennium Pharmaceuticals, Inc. Compounds useful as antagonists of ccr2
US8211912B2 (en) * 2007-09-26 2012-07-03 Gemin X Pharmaceuticals Canada Compositions and methods for effecting NAD+ levels using a nicotinamide phosphoribosyl tranferase inhibitor
EP2213288A1 (en) * 2009-01-30 2010-08-04 Karl Welte NAMPT and vitamin B3 for treating or preventing diseases
CA2768338A1 (en) 2009-07-17 2011-01-20 Topotarget A/S Method for predicting the utility of administering nicotinic acid or a precursor or prodrug thereof to reduce the severity of side-effects of cancer treatment with nicotinamide phosphoribosyltransferase inhibitors
US8912184B1 (en) 2010-03-01 2014-12-16 Alzheimer's Institute Of America, Inc. Therapeutic and diagnostic methods
US9889222B2 (en) 2011-11-09 2018-02-13 Kimberly-Clark Worldwide, Inc. Aqueous medium-sensitive coating compositions for triggered release of active ingredients and visual indication for wetness
US8791045B2 (en) 2011-11-09 2014-07-29 Kimberly-Clark Worldwide, Inc. Non-tacky wetness indicator composition for application on a polymeric substrate
US9585826B2 (en) 2012-11-07 2017-03-07 Kimberly-Clark Worldwide, Inc. Triggerable compositions for two-stage, controlled release of active chemistry
US9938258B2 (en) 2012-11-29 2018-04-10 Karyopharm Therapeutics Inc. Substituted 2,3-dihydrobenzofuranyl compounds and uses thereof
US9856241B2 (en) 2013-07-03 2018-01-02 Karyopharm Therapeutics Inc. Substituted benzofuranyl and benzoxazolyl compounds and uses thereof
WO2015042414A1 (en) 2013-09-20 2015-03-26 Karyopharm Therapeutics Inc. Multicyclic compounds and methods of using same
US9119780B2 (en) 2013-10-30 2015-09-01 Kimberly-Clark Worldwide, Inc. Triggerable compositions for two-stage, controlled release of proactive chemistry
JP2018528196A (ja) 2015-08-18 2018-09-27 カリオファーム セラピューティクス，インコーポレイテッド 癌の治療のための（ｓ，ｅ）−３−（６−アミノピリジン−３−イル）−ｎ−（（５−（４−（３−フルオロ−３−メチルピロリジン−１−カルボニル）フェニル）−７−（４−フルオロフェニル）ベンゾフラン−２−イル）メチル）アクリルアミド
WO2017117447A1 (en) 2015-12-31 2017-07-06 Karyopharm Therapeutics Inc. Multicyclic compounds and uses thereof
RU2651047C1 (ru) * 2017-05-04 2018-04-18 Общество С Ограниченной Ответственностью "Научно-Технологическая Фармацевтическая Фирма "Полисан" Лекарственная композиция цитопротекторного действия и способ ее получения
EP3749306B1 (en) 2018-02-05 2025-09-03 The Trustees of Indiana University Nicotinamide phosphoribosyltransferase inhibitors and methods for use of the same
CN115177594B (zh) * 2022-07-04 2023-08-15 武汉大学中南医院 一种阿昔替尼药物制剂及其制备方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3148115A (en) * 1958-12-08 1964-09-08 Horner Frank W Ltd Potentiation of tumor-growth inhibition from deoxypyridoxine, testosterone, or 6-mercaptopurine, by 6-aminonicotinamide
JPH04103538A (ja) * 1990-08-24 1992-04-06 Ajinomoto Co Inc 制癌剤副作用抑制剤
US5547927A (en) * 1993-05-28 1996-08-20 Abbott Laboratories Enteral nutritional product for patients undergoing radiation therapy and/or chemotherapy
KR100290129B1 (ko) * 1994-08-12 2001-05-15 마이클 바마트 옥시퓨린 누클레오시드로 패혈증 또는 염증성 질병을 치료하는 방법
JPH0881371A (ja) * 1994-09-09 1996-03-26 Suntory Ltd 造血機能亢進剤
EP0800829B2 (en) * 1994-12-29 2012-07-25 Chugai Seiyaku Kabushiki Kaisha Use of a pm-1 antibody or of a mh 166 antibody for enhancing the anti-tumor effect of cisplatin or carboplatin
JP3119430B2 (ja) * 1995-07-25 2000-12-18 大鵬薬品工業株式会社 水酸基ラジカル消去剤
JP2860637B2 (ja) * 1995-12-11 1999-02-24 末綱 陽子 新規なペプチドおよび活性化酸素阻害剤
JP3836203B2 (ja) * 1995-12-20 2006-10-25 日本臓器製薬株式会社 活性酸素・フリーラジカル消去剤
DE19624659A1 (de) * 1996-06-20 1998-01-08 Klinge Co Chem Pharm Fab Neue Pyridylalken- und Pyridylalkinsäureamide
DE19624668A1 (de) * 1996-06-20 1998-02-19 Klinge Co Chem Pharm Fab Verwendung von Pyridylalkan-, Pyridylalken- bzw. Pyridylalkinsäureamiden
US6451816B1 (en) * 1997-06-20 2002-09-17 Klinge Pharma Gmbh Use of pyridyl alkane, pyridyl alkene and/or pyridyl alkine acid amides in the treatment of tumors or for immunosuppression
DE19624704A1 (de) * 1996-06-20 1998-01-08 Klinge Co Chem Pharm Fab Neue Pyridylalkansäureamide
JPH1036260A (ja) * 1996-07-18 1998-02-10 Mitsui Norin Kk 抗ガン剤の効力増強方法
JPH1045594A (ja) * 1996-07-30 1998-02-17 Mitsubishi Gas Chem Co Inc 活性酸素消去剤

Also Published As

Publication number Publication date
DE69928660D1 (de) 2006-01-05
DE69928660T2 (de) 2006-09-14
EP1079832A1 (en) 2001-03-07
JP2002512190A (ja) 2002-04-23
DE19818044A1 (de) 1999-10-28
AU3928299A (en) 1999-11-08
WO1999053920A1 (en) 1999-10-28
ES2253890T3 (es) 2006-06-01
EP1079832B1 (en) 2005-11-30
US20100227896A1 (en) 2010-09-09
DK1079832T3 (da) 2006-04-03
ATE311186T1 (de) 2005-12-15

Similar Documents

Publication Publication Date Title
JP4607319B2 (ja) ビタミンｐｐ化合物の使用
JP4855576B2 (ja) ピペラジニル−置換ピリジルアルカン、アルケンおよびアルキンカルボキサミド類
AU736206B2 (en) Pyridyl alkene- and pyridyl alkine- acid amides as cytostatics and immunosuppressives
EP0912176B1 (en) Use of pyridyl alkane, pyridyl alkene and/or pyridyl alkine acid amides in the treatment of tumors or for immunosuppression
JP4838934B2 (ja) 細胞増殖抑制剤及び免疫抑制剤として有用なアリール−置換ピリジルアルカン、アルケン及びアルキンカルボキサミド類
JP4570247B2 (ja) 新規なピペリジニル−置換ピリジルアルカン、アルケン及びアルキンカルボキサミド類
EP0934309B1 (en) New pyridyl alkane acid amides as cytostatics and immunosuppressives
JP5180816B2 (ja) 神経変性疾患および認知症のためのジヒドロピリジン化合物
DE69823229T2 (de) Zyklisch imid-substituierte pyridylalkan-, alken-, und alkin- carboxamid-derivate, verwendbar als zytostatische und immunosuppressive mittel
SK8982000A3 (en) Combination of benzocycloheptapyridine compounds and antineoplastic drugs for treating proliferative diseases
KR100478405B1 (ko) 세포분열억제제및면역억제제로서의피리딜알켄-및피리딜알킨-산아미드
HK1021974B (en) Pyridyl alkene-and pyridyl alkine-acid amides as cytostatics and immunosuppressives

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20060419

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20060419

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20070605

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20090630

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20090929

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20091006

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20091225

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100104

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20100309

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20100427

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20100510

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100901

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20100928

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20101007

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20131015

Year of fee payment: 3

LAPS Cancellation because of no payment of annual fees